Histidine-Rich Glycoprotein Prevents Septic Lethality through Regulation of Immunothrombosis and Inflammation

EBioMedicine

Volumn 9, Issue , 2016, Pages 180-194

  Wake, Hidenori ^a   Mori, Shuji ^b   Liu, Keyue ^a   Morioka, Yuta ^a   Teshigawara, Kiyoshi ^a   Sakaguchi, Masakiyo ^a   Kuroda, Kosuke ^a   Gao, Yuan ^a   Takahashi, Hideo ^c   Ohtsuka, Aiji ^a   Yoshino, Tadashi ^a   Morimatsu, Hiroshi ^a   Nishibori, Masahiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b SHUJITSU UNIVERSITY   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

ARDS; Histidine rich glycoprotein; Immunothrombosis; Neutrophil; Sepsis

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTITHROMBIN III; F ACTIN; FIBRINOGEN; GLYCOPROTEIN IB; HISTIDINE RICH GLYCOPROTEIN; IMIPENEM; IMMUNOGLOBULIN G; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; LEUKOCYTE ELASTASE; MYELOPEROXIDASE; PADGEM PROTEIN; PHOSPHATIDYLSERINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; HISTIDINE-RICH PROTEINS; PROTEIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CELL ADHESION ASSAY; CELL DEATH; CELL INTERACTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE STORM; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; ILLNESS BEHAVIOR; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOTHROMBOSIS; INFLAMMATION; LEUKOCYTE COUNT; LUNG EMBOLISM; LUNG WEIGHT; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REAL TIME POLYMERASE CHAIN REACTION; RNAI THERAPEUTICS; SURVIVAL RATE; THROMBOCYTE COUNT; VEIN THROMBOSIS; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CELL ADHESION; CELL LINE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LUNG; METABOLISM; MORTALITY; NEUTROPHIL; PATHOLOGY; PNEUMONIA; RNA INTERFERENCE; SEPSIS; SIGNAL TRANSDUCTION; THROMBOSIS;

ANIMALS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; LUNG; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NEUTROPHILS; P-SELECTIN; PNEUMONIA; PROTEINS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; THROMBOSIS;

EID: 84991628546     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.06.003     Document Type: Article

References (47)

1. Alves-Filho, J.C., de Freitas, A., Spiller, F., Souto, F.O., Cunha, F.Q., The role of neutrophils in severe sepsis. Shock 1 (2008), 3–9.
2. Amulic, B., Cazalet, C., Hayes, G.L., Metzler, K.D., Zychlinsky, A., Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 30 (2012), 459–489.
3. Aziz, M., Jacob, A., Yang, W.L., Matsuda, A., Wang, P., Current trends in inflammatory and immunomodulatory mediators in sepsis. J. Leukoc. Biol. 93 (2013), 329–342.
4. Borza, D.B., Tatum, F.M., Morgan, W.T., Domain structure and conformation of histidine-proline-rich glycoprotein. Biochemistry 35 (1996), 1925–1934.
5. Bosshart, H., Heinzelmann, M., Endotoxin-neutralizing effects of histidine-rich peptides. FEBS Lett. 553 (2003), 135–140.
6. Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D.S., Weinrauch, Y., Zychlinsky, A., Neutrophil extracellular traps kill bacteria. Science 303 (2004), 1532–1535.
7. Dellinger, R.P., Levy, M.M., Rhodes, A., Annane, D., Gerlach, H., Opal, S.M., Sevransky, J.E., Sprung, C.L., Douglas, I.S., Jaeschke, R., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med. 41 (2012), 580–637.
8. DiStasi, M.R., Ley, K., Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability. Trends Immunol. 30 (2009), 547–556.
9. Doñate, F., Juarez, J.C., Guan, X., Shipulina, N.V., Plunkett, M.L., Tel-Tsur, Z., Shaw, D.E., Morgan, W.T., Mazar, A.P., Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities. Cancer Res. 64 (2004), 5812–5817.
10. Engelmann, B., Massberg, S., Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13 (2013), 34–45.
11. Gorgani, N.N., Parish, C.R., Easterbrook, Smith, S.B., Altin, J.G., Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes. Biochemistry 36 (1997), 6653–6662.
12. Grommes, J., Soehnlein, O., Contribution of neutrophils to acute lung injury. Mol. Med. 17 (2011), 293–307.
13. Hotchkiss, R.S., Monneret, G., Payen, D., Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13 (2013), 260–268.
14. Juarez, J.C., Guan, X., Shipulina, N.V., Plunkett, M.L., Parry, G.C., Shaw, D.E., Zhang, J.C., Rabbani, S.A., McCrae, K.R., Mazar, A.P., et al. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res. 62 (2002), 5344–5350.
15. Kacprzyk, L., Rydengård, V., Mörgelin, M., Davoudi, M., Pasupuleti, M., Malmsten, M., Schmidtchen, A., Antimicrobial activity of histidine-rich peptides is dependent on acidic conditions. Biochim. Biophys. Acta 1768 (2007), 2667–2680.
16. Koide, T., Foster, D., Yoshitake, S., Davie, E.W., Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry 25 (1986), 2220–2225.
17. Leung, L.L., Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J. Clin. Invest. 77 (1986), 1305–1311.
18. Levy, M.M., Fink, M.P., Marshall, J.C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S.M., Vincent, J.L., Ramsay, G., 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31 (2003), 1250–1256.
19. Lijnen, H.R., Hoylaerts, M., Collen, D., Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J. Biol. Chem. 258 (1983), 3803–3808.
20. Matthay, M.A., Zemans, R.L., The acute respiratory distress syndrome: pathogenesis and treatment. Annu. Rev. Pathol. 6 (2011), 147–163.
21. Moreland, J.G., Bailey, G., Nauseef, W.M., Weiss, J.P., Organism-specific neutrophil-endothelial cell interactions in response to Escherichia coli, Streptococcus pneumoniae, and Staphylococcus aureus. J. Immunol. 172 (2004), 426–432.
22. Morgan, W.T., The histidine-rich glycoprotein of serum has a domain rich in histidine, proline, and glycine that binds heme and metals. Biochemistry 24 (1985), 1496–1501.
23. Mori, S., Takahashi, H.K., Yamaoka, K., Okamoto, M., Nishibori, M., High affinity binding of serum histidine-rich glycoprotein to nickel-nitrilotriacetic acid: the application to microquantification. Life Sci. 73 (2003), 93–102.
24. Opal, S.M., van der Poll, T., Endothelial barrier dysfunction in septic shock. J. Intern. Med. 277 (2015), 277–293.
25. Opal, S.M., Laterre, P.F., Francois, B., LaRosa, S.P., Angus, D.C., Mira, J.P., Wittebole, X., Dugernier, T., Perrotin, D., Tidswell, M., et al. Effect of Eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis. JAMA 309 (2013), 1154–1162.
26. Peterson, C.B., Morgan, W.T., Blackburn, M.N., Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. Evidence for a mechanism involving competition with both antithrombin and thrombin for heparin binding. J. Biol. Chem. 262 (1987), 7567–7574.
27. Phillipson, M., Kubes, P., The neutrophil in vascular inflammation. Nat. Med. 17 (2011), 1381–1390.
28. Piccinini, A.M., Midwood, K.S., DAMPening inflammation by modulating TLR signalling. Mediat. Inflamm. 2010 (2010), 1–21.
29. Poon, I.K., Hulett, M.D., Parish, C.R., Histidine-rich glycoprotein is a novel plasma pattern recognition molecule that recruits IgG to facilitate necrotic cell clearance via FcgammaRI on phagocytes. Blood 115 (2010), 2473–2482.
30. Poon, I.K., Patel, K.K., Davis, D.S., Parish, C.R., Hulett, M.D., Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. Blood 117 (2011), 2093–2101.
31. Ranieri, V.M., Thompson, B.T., Barie, P.S., Dhainaut, J.F., Douglas, I.S., Finfer, S., Gårdlund, B., Marshall, J.C., Rhodes, A., Artigas, A., et al. Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 366 (2012), 2055–2064.
32. Rice, T.W., Wheeler, A.P., Bernard, G.R., Vincent, J.L., Angus, D.C., Aikawa, N., Demeyer, I., Sainati, S., Amlot, N., Cao, C., et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med. 38 (2010), 1685–1694.
33. Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M.L., Segura, I., Li, X., Knevels, E., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19 (2011), 31–44.
34. Russell, J.A., Management of sepsis. N. Engl. J. Med. 355 (2006), 1699–1713.
35. Rydengård, V., Olsson, A.K., Mörgelin, M., Schmidtchen, A., Histidine-rich glycoprotein exerts antibacterial activity. FEBS J. 274 (2007), 377–389.
36. Rydengård, V., Shannon, O., Lundqvist, K., Kacprzyk, L., Chalupka, A., Olsson, A.K., Mörgelin, M., Jahnen-Dechent, W., Malmsten, M., Schmidtchen, A., Histidine-rich glycoprotein protects from systemic Candida infection. PLoS Pathog., 4, 2008, e1000116.
37. Saigo, K., Yoshida, A., Ryo, R., Yamaguchi, N., Leung, L.L., Histidine-rich glycoprotein as a negative acute phase reactant. Am. J. Hematol. 34 (1990), 149–150.
38. Salomão, R., Martins, P.S., Brunialti, M.K., Fernandes, Mda, L., Martos, L.S., Mendes, M.E., Gomes, N.E., Rigato, O., TLR signaling pathway in patients with sepsis. Shock 30 (2008), 73–77.
39. Semeraro, N., Ammollo, C.T., Semeraro, F., Colucci, M., Sepsis, thrombosis and organ dysfunction. Thromb. Res. 129 (2012), 290–295.
40. Shannon, O., Rydengård, V., Schmidtchen, A., Mörgelin, M., Alm, P., Sørensen, O.E., Björck, L., Histidine-rich glycoprotein promotes bacterial entrapment in clots and decreases mortality in a mouse model of sepsis. Blood 116 (2010), 2365–2372.
41. Silverstein, R.L., Leung, L.L., Harpel, P.C., Nachman, R.L., Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein. J. Clin. Invest. 75 (1985), 2065–2073.
42. Sudom, K., Turrin, N.P., Hayley, S., Anisman, H., Influence of chronic interleukin-2 infusion and stressors on sickness behaviors and neurochemical change in mice. Neuroimmunomodulation 11 (2004), 341–350.
43. Tugues, S., Roche, F., Noguer, O., Orlova, A., Bhoi, S., Padhan, N., Akerud, P., Honjo, S., Selvaraju, R.K., Mazzone, M., et al. Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes. PLoS One, 9, 2014, e107483.
44. Wake, H., Mori, S., Liu, K., Takahashi, H.K., Nishibori, M., Histidine-rich glycoprotein inhibited high mobility group box 1 in complex with heparin-induced angiogenesis in matrigel plug assay. Eur. J. Pharmacol. 623 (2009), 89–95.
45. Ward, P.A., New approaches to the study of sepsis. EMBO Mol. Med. 4 (2012), 1234–1243.
46. Williams, M.R., Azcutia, V., Newton, G., Alcaide, P., Luscinskas, F.W., Emerging mechanisms of neutrophil recruitment across endothelium. Trends Immunol. 32 (2011), 461–469.
47. Yipp, B.G., Kubes, P., NETosis: how vital is it?. Blood 122 (2013), 2784–2794.